Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.

Akiyama, Hiroki; Nishimura, Akihiro; Morita, Naru; Yajima, Toshitaka

Akiyama, Hiroki; Nishimura, Akihiro; Morita, Naru; Yajima, Toshitaka.

Affiliation

Akiyama H; Medical Affairs, AstraZeneca K.K., Osaka, Japan.
Nishimura A; Medical Affairs, AstraZeneca K.K., Osaka, Japan.
Morita N; Department of Internal Medicine, Urayasu Central Hospital, Chiba, Japan.
Yajima T; Medical Affairs, AstraZeneca K.K., Osaka, Japan.

Front Endocrinol (Lausanne) ; 14: 1111984, 2023.

Article in En | MEDLINE | ID: mdl-36793276

Subject(s)

Diabetes Mellitus, Type 2; Heart Failure; Metabolic Syndrome; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Humans; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use; Sodium-Glucose Transporter 2 Inhibitors/pharmacology; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/drug therapy; Glucose/therapeutic use; Blood Glucose; Metabolic Syndrome/drug therapy; Quality of Life; Renal Insufficiency, Chronic/complications; Renal Insufficiency, Chronic/drug therapy; Sodium

Key words

SGLT2 inhibitor; cardio-renal-metabolic syndrome; cardiorenal protection; chronic heart failure; chronic kidney disease

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Metabolic Syndrome / Symporters / Diabetes Mellitus, Type 2 / Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors / Heart Failure Type of study: Clinical_trials Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2023 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google